Intercept Pharmaceuticals, Inc. (ICPT) Insider Rachel Mcminn Sells 283 Shares of Stock
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) insider Rachel Mcminn sold 283 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.89, for a total transaction of $16,665.87. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Rachel Mcminn also recently made the following trade(s):
- On Monday, July 31st, Rachel Mcminn sold 130 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $123.12, for a total transaction of $16,005.60.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded up 5.34% on Thursday, hitting $72.40. 2,882,026 shares of the stock were exchanged. The company’s market cap is $1.82 billion. Intercept Pharmaceuticals, Inc. has a 12 month low of $54.98 and a 12 month high of $156.65. The company has a 50-day moving average price of $94.11 and a 200 day moving average price of $111.08.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same period last year, the business earned ($3.14) EPS. Equities analysts forecast that Intercept Pharmaceuticals, Inc. will post ($13.98) EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of ICPT. MARSHALL WACE ASIA Ltd purchased a new stake in Intercept Pharmaceuticals during the 1st quarter valued at about $13,012,000. Marshall Wace North America L.P. purchased a new stake in Intercept Pharmaceuticals during the 1st quarter valued at about $13,012,000. Balyasny Asset Management LLC purchased a new stake in Intercept Pharmaceuticals during the 2nd quarter valued at about $13,766,000. Macquarie Group Ltd. grew its position in Intercept Pharmaceuticals by 54.2% during the 1st quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after purchasing an additional 84,954 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after purchasing an additional 57,149 shares during the last quarter. Institutional investors own 82.19% of the company’s stock.
ICPT has been the topic of a number of research analyst reports. Cowen and Company restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, June 12th. Wedbush restated an “outperform” rating and issued a $231.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, June 13th. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a research report on Monday, July 10th. They issued a “buy” rating and a $275.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 target price on the stock in a research report on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $162.88.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.